Leishmaniasis and Chagas Disease Treatment
- Authors: Maria Carolina Accioly Brelaz de Castro, Aline Caroline da Silva, Thiago Andre Ramos dos Santos, Cíntia Nascimento da Costa Oliveira, Rayana Carla Silva de Morais, Milena de Paiva Cavalcanti, Valeria Rego Alves Pereira7
-
View Affiliations Hide Affiliations7 Immunology department, Aggeu Magalhaes Research Center, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil.
- Source: Tropical Diseases: An Overview of Major Diseases Occurring in the Americas , pp 114-128
- Publication Date: December 2017
- Language: English
Leishmaniasis and Chagas Disease Treatment, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781681085876/chapter-4-1.gif
Leishmaniasis and trypanosomiasis are challenges among neglected tropical diseases. They usually affect marginal and poor populations and have the potential of becoming lethal. Current treatment for both diseases is based on chemotherapy, with the drug of choice being pentavalent antimonials for leishmaniasis, while for Chagas disease the two nitro-heterocyclic drugs, Benznidazole and Nifurtimox are recommended. The limited number, low efficacy, and side effects of conventional anti-Leishmania and anti-Trypanosomal drugs and the resistance developed by parasites are the major factors responsible for the growth in mortality rates. Currently there is an urgent need to develop effective, safe, cost-effective drugs, and new treatment schemes, as well as vaccines. As a result, international health organizations, universities, foundations, and pharmaceutical corporations are working together to support analysis and development of new strategies for controlling these diseases.
-
From This Site
/content/books/9781681085876.chapter-4dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
